The results of the oral direct THRombin Inhibitor ximelagatran for Venous thromboEmbolism Treatment (THRIVE Treatment) phase 3 study show that ximelagatran, the first of a new class of oral direct ...

Purpose: The chemistry, pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, contraindications, and adverse effects of ximelagatran are reviewed. Summary: Ximelagatran is the ...

The most common underlying pathophysiologic process in patients with unstable angina (UA) or non-ST-segment elevation myocardial infarction (NSTEMI) involves the formation of nonocclusive thrombus at ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Argatroban could ...

Groundbreaking results in the RE-LY® trial - novel oral direct thrombin inhibitor dabigatran etexilate convincingly beats warfarin - superior stroke reduction with less bleeding Significant reduction ...

17th International Congress on Thrombosis, Bologna, 26 October 2002: Important results from the EXPRESS clinical trial for the oral direct thrombin inhibitor (Oral DTI), EXANTA™ (oral ximelagatran and ...

(San Diego, Calif., December 7, 2003) – The use of ximelagatran in patients with acute venous thromboembolism is as safe and effective as the current standard treatment of enoxaparin, according to a ...

Ingelheim/Germany, 14 September 2007 – Boehringer Ingelheim today announced the publication of the RE-NOVATE study in the September 15 issue of The Lancet1. The results demonstrate that the oral ...

New research discovered a unique class of medications that act as blood thinners by inhibiting an enzyme in the genes of tick saliva. The research focused on novel direct thrombin inhibitors from tick ...

SOUTH SAN FRANCISCO, Calif., July 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new in vitro data establishing the relationship between concentrations of the ...